Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes.

Amrit ChowdharySharmaine ThirunavukarasuTobin JosephNicholas JexSindhoora KothaMarilena GiannoudiHenry ProcterLizette CashSevval AkkayaDavid BroadbentHui XuePeter SwobodaLadislav ValkovičPeter KellmanSven PleinOliver J RiderStefan NeubauerJohn P GreenwoodEylem Levelt

Published in: Journal of the American College of Cardiology (2024)

Liraglutide treatment resulted in improved myocardial perfusion, energetics, and 6-minute walk distance in patients with T2D, whereas pioglitazone showed no effect on these parameters (Lean-DM [Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes]; NCT04657939).

Keyphrases

bone mineral density
single cell
high intensity
cell therapy
cancer therapy
stem cells
type diabetes
skeletal muscle
body composition
drug delivery
adipose tissue
resistance training
insulin resistance
replacement therapy
glycemic control